Dirk Sibbing on The Importance of ISAR-REACT 5 trial and 2020 ESC Guidelines for ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Very impressive and important data published in EuroIntervention today, showing how impactful data from randomized trials can be…
In 2019, the randomized ISAR-REACT 5 trial demonstrated superiority of prasugrel over ticagrelor for treatment of ACS patients undergoing PCI
In consequence, the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation included a new COR IIa in preference for prasugrel for ACS-PCI
Then, an entire (!) country (Denmark) shifted treatment from routine use of ticagrelor over to prasugrel.
Results of this „real-life“ experiment are now published in Eurointervention
In 10,984 patients, prasugrel was associated with reduced 1-year rate of MACE (adjHR 0.67) and MI (adjHR 0.65), without differences in bleeding risk.
Risk reductions from randomized (ISAR-REACT 5) vs. observational data (Denmark) were very similar, thereby supporting current guideline recommendations
A great example for how impactful clinical trial data can be for the benefit of our patients.”
Read the full article here.
Article: Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study
Authors: Mia Ravn Jacobsen, Peter Laursen Graversen, Reza Jabbari, Erik Lerkevang Grove, Charlotte Glinge, Lene Holmvang, Tobias Geisler, Lars Køber, Christian Torp-Pedersen, Thomas Engstrøm, Rikke Sørensen
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
May 13, 2026, 17:38Rohit Sankar J. Snscphysio: Recognizing the Clot Before It Becomes Life-Threatening
-
May 13, 2026, 16:41Seema Dawood: When Elevated Platelets Signal a Myeloproliferative Neoplasm
-
May 13, 2026, 16:38Kari Tikkinen: Defining Thromboprophylaxis in MIBC Neoadjuvant Care
-
May 13, 2026, 16:28Nadia Tarhini: Evaluating the Risk of Recurrent Thrombosis in Children with ALL
-
May 13, 2026, 16:01Sifat Jubaira: When Low MCV Meets High Platelets
-
May 13, 2026, 15:58Aktham El-rekaby: Immunothrombosis in Acute Ischaemic Stroke
-
May 13, 2026, 15:49Alison Dougall: Oral Health and Cardiovascular Risk in Bleeding Disorders
-
May 13, 2026, 15:38International Journal of Stroke: Oral Anticoagulants and DOAC–Antiplatelet Therapy Are Associated with Increased Major Bleeding Risk
-
May 13, 2026, 15:19Papa Heme։ Causes of Isolated Prolonged aPTT Without Bleeding